US Stock MarketDetailed Quotes
INBX Inhibrx Biosciences
- 15.200
- +0.140+0.93%
Close Sep 9 16:00 ET
- 15.200
- 0.0000.00%
Post 16:00 ET
220.03MMarket Cap0.13P/E (TTM)
15.730High15.010Low126.37KVolume15.240Open15.060Pre Close1.93MTurnover1.63%Turnover RatioLossP/E (Static)14.48MShares18.95052wk High1.00P/B118.19MFloat Cap10.80052wk Low--Dividend TTM7.78MShs Float18.950Historical High--Div YieldTTM4.78%Amplitude10.800Historical Low15.282Avg Price1Lot Size
Inhibrx Biosciences Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|
| Total revenue | 233.33%100K | 0 | 25.60%1.63M | 30K | 0 | 1.3M |
| Operating revenue | 233.33%100K | --0 | 25.60%1.63M | --30K | --0 | --1.3M |
| Cost of revenue | ||||||
| Gross profit | ||||||
| Operating expense | 289.18%161M | 24.46%49.21M | 32.37%154.38M | 41.37M | 39.54M | 116.62M |
| Selling and administrative expenses | 1,185.50%93.37M | 64.64%8.78M | 61.28%24.25M | --7.26M | --5.33M | --15.04M |
| -General and administrative expense | 1,185.50%93.37M | 64.64%8.78M | 61.28%24.25M | --7.26M | --5.33M | --15.04M |
| Research and development costs | 98.30%67.63M | 18.20%40.43M | 28.08%130.13M | --34.11M | --34.21M | --101.6M |
| Other operating expenses | ---- | ---- | ---- | ---- | ---- | ---14K |
| Operating profit | -289.22%-160.9M | -24.46%-49.21M | -32.45%-152.75M | -41.34M | -39.54M | -115.32M |
| Net non-operating interest income expense | 52.29%-2.62M | -5.49M | ||||
| Non-operating interest income | 13.55%2.74M | ---- | ---- | --2.41M | ---- | ---- |
| Non-operating interest expense | -32.18%5.36M | ---- | ---- | --7.91M | ---- | ---- |
| Other net income (expense) | 931,681.11%2.02B | 15.71%-59K | -58,100.00%-580K | -217K | -70K | 1K |
| Special income (charges) | --2.02B | ---- | ---- | --0 | ---- | ---- |
| -Less：Restructuring and merger&acquisition | ---2.02B | ---- | ---- | --0 | ---- | ---- |
| Other non- operating income (expenses) | 115.21%33K | 15.71%-59K | -58,100.00%-580K | ---217K | ---70K | --1K |
| Income before tax | 4,049.27%1.86B | -24.39%-49.27M | -32.96%-153.33M | -47.05M | -39.61M | -115.32M |
| Income tax | -60.00%2K | 0.00%3K | 5K | 3K | ||
| Earnings from equity interest net of tax | ---- | ---- | ---1.63M | ---- | ---- | --0 |
| Net income | 4,048.85%1.86B | -24.39%-49.27M | -34.37%-154.96M | -47.05M | -39.61M | -115.33M |
| Net income continuous Operations | 4,048.85%1.86B | -24.39%-49.27M | -34.37%-154.96M | ---47.05M | ---39.61M | ---115.33M |
| Minority interest income | ||||||
| Net income attributable to the parent company | 4,048.85%1.86B | -24.39%-49.27M | -34.37%-154.96M | -47.05M | -39.61M | -115.33M |
| Preferred stock dividends | ||||||
| Other preferred stock dividends | ||||||
| Net income attributable to common stockholders | 4,048.85%1.86B | -24.39%-49.27M | -34.37%-154.96M | -47.05M | -39.61M | -115.33M |
| Basic earnings per share | 3,946.92%127.1 | -24.39%-3.4599 | -34.37%-10.8814 | -3.3039 | -2.7814 | -8.098 |
| Diluted earnings per share | 3,897.89%125.48 | -24.39%-3.4599 | -34.37%-10.8814 | -3.3039 | -2.7814 | -8.098 |
| Dividend per share | ||||||
| Currency Unit | USD | USD | USD | USD | USD | USD |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
